NVZMF OTC
Novozymes A/S
1W: -3.7%
1M: -8.4%
3M: +1.7%
YTD: +5.2%
1Y: +8.0%
3Y: +66.7%
5Y: -4.4%
$65.11
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$4.2B
-85.5% ▼
5Y CAGR: -21.6%
Gross Profit
$2.2B
-84.9% ▼
5Y CAGR: -22.2%
Operating Income
$883M
-76.4% ▼
5Y CAGR: -24.7%
Net Income
$584M
-74.4% ▼
5Y CAGR: -27.1%
EPS (Diluted)
$1.25
+86.6% ▲
5Y CAGR: -34.1%
EBITDA
$18.9B
+134.7% ▲
5Y CAGR: +32.2%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $15.0B | $17.6B | $17.9B | $28.6B | $4.2B |
| YoY Growth | +6.7% | +17.4% | +2.0% | +59.7% | -85.5% |
| Cost of Revenue | $6.3B | $8.0B | $8.2B | $13.7B | $1.9B |
| Gross Profit | $8.6B | $9.6B | $9.7B | $14.9B | $2.2B |
| Gross Margin | 57.8% | 54.6% | 54.3% | 52.0% | 53.9% |
| R&D Expenses | $2.0B | $2.0B | $2.0B | $3.1B | -$432M |
| SG&A Expenses | $2.8B | $3.2B | $3.3B | $5.7B | $912M |
| Operating Expenses | $4.6B | $5.0B | $5.7B | $11.1B | $1.4B |
| Operating Income | $4.0B | $4.6B | $4.0B | $3.7B | $883M |
| Operating Margin | 26.8% | 26.0% | 22.2% | 13.1% | 21.2% |
| Interest Expense | $102M | $102M | $23M | $76M | $68M |
| Income Before Tax | $3.9B | $4.6B | $3.9B | $3.1B | $743M |
| Tax Expense | $779M | $870M | $871M | $830M | $160M |
| Net Income | $3.1B | $3.7B | $3.0B | $2.3B | $584M |
| Net Margin | 21.0% | 20.9% | 16.9% | 8.0% | 14.0% |
| EPS (Diluted) | $11.23 | $13.19 | $10.88 | $0.67 | $1.25 |
| EBITDA | $5.1B | $5.7B | $5.6B | $8.1B | $18.9B |
| Shares Outstanding | 280M | 279M | 278M | 456M | 467M |